DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
OPRX logo

OptimizeRx Corporation Stock Price

NasdaqCM:OPRX Community·US$135.1m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

OPRX Share Price Performance

US$7.18
-11.65 (-61.87%)
​
US$11.50
Fair Value
US$7.18
-11.65 (-61.87%)
37.6% undervalued intrinsic discount
US$11.50
Fair Value
Price US$7.18
AnalystConsensusTarget US$11.50
AnalystLowTarget US$9.00
AnalystHighTarget US$18.00
Tue, 16 Jun 26
Fair ValueUS$11.50
Share Pricen/a

OPRX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$11.5 37.6% undervalued intrinsic discount

Pharmaceutical Digital Engagement Will Unlock Future Value

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$9 20.2% undervalued intrinsic discount

Heightened Data Privacy And Provider Skepticism Will Hinder Healthcare Transformation

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$18 60.1% undervalued intrinsic discount

Digital Health Adoption And AI Will Drive Secular Expansion

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
OPRX logo
OptimizeRx
37.6% undervalued intrinsic discount

Pharmaceutical Digital Engagement Will Unlock Future Value

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 16 Jun
Read Narrative
OPRX logo
OptimizeRx
20.2% undervalued intrinsic discount

Heightened Data Privacy And Provider Skepticism Will Hinder Healthcare Transformation

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 30 Jun
Read Narrative
OPRX logo
OptimizeRx
60.1% undervalued intrinsic discount

Digital Health Adoption And AI Will Drive Secular Expansion

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 2 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
OPRX logo

OPRX: Workflow Data And AI Tools Will Support Long Term Earnings Power

Fair Value: US$9 20.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
OPRX logo

OPRX: Profit Execution And Programmatic Ramp Will Support Future Upside

Fair Value: US$11.5 37.6% undervalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
OPRX logo

OPRX: Profit Stability And Buybacks Will Support Programmatic Recovery Potential

Fair Value: US$18 60.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Good value with adequate balance sheet.

0 Risks
3 Rewards
View Full Analysis

OptimizeRx Corporation Key Details

US$98.7m

Revenue

US$26.4m

Cost of Revenue

US$72.2m

Gross Profit

US$67.6m

Other Expenses

US$4.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.24
73.22%
4.66%
14.5%
View Full Analysis

About OPRX

Founded
2006
Employees
133
CEO
Stephen Silvestro
WebsiteView website
www.optimizerx.com

OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers’ target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Recent OPRX News & Updates

Recent updates

No updates

OptimizeRx Corporation Competitors

CYH logo

Community Health Systems

Symbol: NYSE:CYH
Market cap: US$399.8m
AUNA logo

Auna

Symbol: NYSE:AUNA
Market cap: US$382.6m
SLP logo

Simulations Plus

Symbol: NasdaqGS:SLP
Market cap: US$372.5m
OFIX logo

Orthofix Medical

Symbol: NasdaqGS:OFIX
Market cap: US$362.9m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide